PEPITEM - Revision history

Dmitry Dzhagarov at 12:02, 19 July 2024

2024-07-19T12:02:14Z

← Older revision		Revision as of 12:02, 19 July 2024
Line 1:		Line 1:
	'''PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration)''' is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.<ref>Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G. E. (2015). Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature medicine, 21(5), 467-475. PMID: 25894827 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425550/ PMC4425550] DOI: 10.1038/nm.3842</ref><ref>Apta, B. H. R. (2015). Investigating the Structure and Function of PEPITEM, a Novel Inhibitor of T cell Transmigration. </ref>		'''PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration)''' is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.<ref>Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G. E. (2015). Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature medicine, 21(5), 467-475. PMID: 25894827 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425550/ PMC4425550] DOI: 10.1038/nm.3842</ref><ref>Apta, B. H. R. (2015). Investigating the Structure and Function of PEPITEM, a Novel Inhibitor of T cell Transmigration. </ref>

	'''PEPITEM supplementation may represent a potential geroprotective agent to rejuvenate immune functions''' since it could fully restore the regulation of lymphocyte migration and thus facilitate and rejuvenate immune responses to diverse stimuli in the aged population.<ref>Hopkin, S.J., Nathan, P., Pezhman, L. et al. (2024). Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention. npj Aging 10, 33 https://doi.org/10.1038/s41514-024-00160-6</ref>		'''PEPITEM supplementation may represent a potential geroprotective agent to rejuvenate immune functions''' since it could fully restore the regulation of lymphocyte migration and thus facilitate and rejuvenate immune responses to diverse stimuli in the aged population.<ref>Hopkin, S.J., Nathan, P., Pezhman, L. et al. (2024). Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention. npj Aging 10, 33 https://doi.org/10.1038/s41514-024-00160-6</ref><ref>Hopkin, S. J. (2023). PEPITEM, a regulator of leukocyte trafficking in ageing (Doctoral dissertation, University of Birmingham). https://etheses.bham.ac.uk/id/eprint/13787/</ref>

	Recent efforts have identified PEPITEM (immunopeptide) for regulation of chronic inflammation in the adiponectin-PEPITEM pathway. The pathway reduced the probability of developing T2D, and fatty liver associated with obesity by enhancing leukocyte access into ATs and inducing reduced inflammatory responses in T2D and other obesity associated disorders (hepatic steatosis).<ref>Pezhman, L., Hopkin, S. J., Begum, J., Heising, S., Nasteska, D., Wahid, M., ... & McGettrick, H. M. (2023). PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clinical and Experimental Immunology, 212(1), 1-10. PMID: 36891817 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081110/ PMC10081110] DOI: 10.1093/cei/uxad022</ref> <ref>~~Hopkin~~, S. J. (~~2023~~). PEPITEM, ~~a regulator of leukocyte trafficking in ageing~~ (~~Doctoral dissertation~~, ~~University of Birmingham).~~ https://~~etheses~~.~~bham~~.ac.~~uk/id/eprint/13787/~~</ref>		Recent efforts have identified PEPITEM (immunopeptide) for regulation of chronic inflammation in the adiponectin-PEPITEM pathway. The pathway reduced the probability of developing T2D, and fatty liver associated with obesity by enhancing leukocyte access into ATs and inducing reduced inflammatory responses in T2D and other obesity associated disorders (hepatic steatosis).<ref>Pezhman, L., Hopkin, S. J., Begum, J., Heising, S., Nasteska, D., Wahid, M., ... & McGettrick, H. M. (2023). PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clinical and Experimental Immunology, 212(1), 1-10. PMID: 36891817 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081110/ PMC10081110] DOI: 10.1093/cei/uxad022</ref>

			PEPITEM therapy halts osteoporosis-induced bone loss and arthritis-induced bone damage in mice models of excessive bone loss and stimulates new bone formation in osteoblasts derived from patient samples.<ref>Lewis, J. W., Frost, K., Neag, G., Wahid, M., Finlay, M., Northall, E. H., ... & McGettrick, H. M. (2024). Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss. Cell Reports Medicine, 5(5), 101574 https://doi.org/10.1016/j.xcrm.2024.101574</ref>

	[[Category:Drafts]]		[[Category:Drafts]]
	[[Category:Drugs]]		[[Category:Drugs]]

Dmitry Dzhagarov at 11:46, 19 July 2024

2024-07-19T11:46:44Z

← Older revision		Revision as of 11:46, 19 July 2024
Line 1:		Line 1:
	PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.<ref>Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G. E. (2015). Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature medicine, 21(5), 467-475. PMID: 25894827 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425550/ PMC4425550] DOI: 10.1038/nm.3842</ref><ref>Apta, B. H. R. (2015). Investigating the Structure and Function of PEPITEM, a Novel Inhibitor of T cell Transmigration. </ref>		'''PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration)''' is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.<ref>Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G. E. (2015). Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature medicine, 21(5), 467-475. PMID: 25894827 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425550/ PMC4425550] DOI: 10.1038/nm.3842</ref><ref>Apta, B. H. R. (2015). Investigating the Structure and Function of PEPITEM, a Novel Inhibitor of T cell Transmigration. </ref>

	PEPITEM supplementation may represent a potential geroprotective agent to rejuvenate immune functions since it could fully restore the regulation of lymphocyte migration and thus facilitate and rejuvenate immune responses to diverse stimuli in the aged population.<ref>Hopkin, S.J., Nathan, P., Pezhman, L. et al. (2024). Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention. npj Aging 10, 33 https://doi.org/10.1038/s41514-024-00160-6</ref>		'''PEPITEM supplementation may represent a potential geroprotective agent to rejuvenate immune functions''' since it could fully restore the regulation of lymphocyte migration and thus facilitate and rejuvenate immune responses to diverse stimuli in the aged population.<ref>Hopkin, S.J., Nathan, P., Pezhman, L. et al. (2024). Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention. npj Aging 10, 33 https://doi.org/10.1038/s41514-024-00160-6</ref>

	Recent efforts have identified PEPITEM (immunopeptide) for regulation of chronic inflammation in the adiponectin-PEPITEM pathway. The pathway reduced the probability of developing T2D, and fatty liver associated with obesity by enhancing leukocyte access into ATs and inducing reduced inflammatory responses in T2D and other obesity associated disorders (hepatic steatosis).<ref>Pezhman, L., Hopkin, S. J., Begum, J., Heising, S., Nasteska, D., Wahid, M., ... & McGettrick, H. M. (2023). PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clinical and Experimental Immunology, 212(1), 1-10. PMID: 36891817 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081110/ PMC10081110] DOI: 10.1093/cei/uxad022</ref> <ref>Hopkin, S. J. (2023). PEPITEM, a regulator of leukocyte trafficking in ageing (Doctoral dissertation, University of Birmingham). https://etheses.bham.ac.uk/id/eprint/13787/</ref>		Recent efforts have identified PEPITEM (immunopeptide) for regulation of chronic inflammation in the adiponectin-PEPITEM pathway. The pathway reduced the probability of developing T2D, and fatty liver associated with obesity by enhancing leukocyte access into ATs and inducing reduced inflammatory responses in T2D and other obesity associated disorders (hepatic steatosis).<ref>Pezhman, L., Hopkin, S. J., Begum, J., Heising, S., Nasteska, D., Wahid, M., ... & McGettrick, H. M. (2023). PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clinical and Experimental Immunology, 212(1), 1-10. PMID: 36891817 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081110/ PMC10081110] DOI: 10.1093/cei/uxad022</ref> <ref>Hopkin, S. J. (2023). PEPITEM, a regulator of leukocyte trafficking in ageing (Doctoral dissertation, University of Birmingham). https://etheses.bham.ac.uk/id/eprint/13787/</ref>

Dmitry Dzhagarov: Created page with "PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G..."

2024-07-19T11:45:48Z

Created page with "PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.<ref>Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G..."

New page

PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) is a B cell-secreted peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, leading to inappropriate T cell trafficking with pathological consequences, e.g. in type-1 diabetes and rheumatoid arthritis.<ref>Chimen, M., McGettrick, H. M., Apta, B., Kuravi, S. J., Yates, C. M., Kennedy, A., ... & Rainger, G. E. (2015). Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease. Nature medicine, 21(5), 467-475. PMID: 25894827 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425550/ PMC4425550] DOI: 10.1038/nm.3842</ref><ref>Apta, B. H. R. (2015). Investigating the Structure and Function of PEPITEM, a Novel Inhibitor of T cell Transmigration. </ref>

PEPITEM supplementation may represent a potential geroprotective agent to rejuvenate immune functions since it could fully restore the regulation of lymphocyte migration and thus facilitate and rejuvenate immune responses to diverse stimuli in the aged population.<ref>Hopkin, S.J., Nathan, P., Pezhman, L. et al. (2024). Rejuvenation of leukocyte trafficking in aged mice through PEPITEM intervention. npj Aging 10, 33 https://doi.org/10.1038/s41514-024-00160-6</ref>

Recent efforts have identified PEPITEM (immunopeptide) for regulation of chronic inflammation in the adiponectin-PEPITEM pathway. The pathway reduced the probability of developing T2D, and fatty liver associated with obesity by enhancing leukocyte access into ATs and inducing reduced inflammatory responses in T2D and other obesity associated disorders (hepatic steatosis).<ref>Pezhman, L., Hopkin, S. J., Begum, J., Heising, S., Nasteska, D., Wahid, M., ... & McGettrick, H. M. (2023). PEPITEM modulates leukocyte trafficking to reduce obesity-induced inflammation. Clinical and Experimental Immunology, 212(1), 1-10. PMID: 36891817 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081110/ PMC10081110] DOI: 10.1093/cei/uxad022</ref> <ref>Hopkin, S. J. (2023). PEPITEM, a regulator of leukocyte trafficking in ageing (Doctoral dissertation, University of Birmingham). https://etheses.bham.ac.uk/id/eprint/13787/</ref>

[[Category:Drafts]]
[[Category:Drugs]]